News

Generic Treprostinil Available as Under-the-skin Injection

Sandoz‘s generic treprostinil injection now is available for subcutaneous (under-the-skin) administration to treat  pulmonary arterial hypertension (PAH), the company announced in a press release. Treprostinil first was approved to treat PAH in the U.S. in 2002. It was developed by United Therapeutics, which markets the…

Repurposed Trifluoperazine (TFP) May Be Effective PAH Therapy

Trifluoperazine or TFP, an approved schizophrenia medication, also may be effective in the treatment of pulmonary arterial hypertension (PAH), a preclinical study suggests. In rat models of PAH, trifluoperazine was found to provide therapeutic benefits — without causing detectable side effects. The study, “Preclinical Investigation of Trifluoperazine…

KER-012 Found to Prevent Increased Scarring in Rat Model of PAH

Keros Therapeutics’ experimental therapy KER-012 prevented increases in the levels of markers for inflammation, fibrosis (scarring), and heart damage in a rat model of pulmonary arterial hypertension (PAH), a study shows. “We believe that the current study supports that KER-012 has the potential to treat PAH in patients without…